Environmental lead contamination lingers despite decades of sharply declining use and release of the metal. As a consequence, low-level lead exposure remains common, with an average adult blood lead level in the general U.S. population of 1-2 μg/dL.
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Current evidence suggests that kidney damage can occur at blood lead levels as low as 5 μg/dL.
2 Specific populations, including people with preexisting kidney disease, diabetes, or hypertension, may be at even greater risk of effects of low-level lead exposure. 2, 3 Both in vivo and in vitro data highlight oxidative stress as a factor in lead-associated kidney damage, but it has been unclear how the stress is generated.
1,2
In the current study, the researchers wove observations from previous investigations into a testable hypothesis. They took into account deposition of iron-presumably from iron-rich red blood cells (erythrocytes)-in kidneys of individuals with renal disorders. They also considered the kidney's role in clearing erythrocytes from circulation as the cells become old or damaged.
During a process ca lled er y throphagoc y tosis, aging erythrocytes are enveloped and broken down by other cells. Erythrophagocytosis occurs primarily in cells of the spleen and liver, but proximal tubular epithelial cells in the kidney also have this capability. The signal that an erythrocyte needs to be removed from circulation comes from a compound called phosphatidylserine (PS). In a normal, healthy erythrocyte, PS is an internal cellular component, with no direct contact with the cell's outer environment. Aged and damaged red blood cells begin to shift PS to the outer surface. Members of this research team previously found that lead exposure was associated with a surge in PS externalization, followed by enhanced erythrophagocytosis in the spleen. 4 In this study the researchers hypothesized that lead exposure increases the number of PS-tagged erythrocytes, which are then consumed by the proximal tubular epithelial cells in the kidney. They further hypothesized that iron from the erythrocytes accumulates in the kidney cells, where it triggers the formation of reactive oxygen species, the first step in oxidative damage.
The ultimate biological outcome of toxic exposures is frequently a combination of two factors-individual responses of multiple tissues and, subsequently, complex interactions of altered tissues-says study coauthor Jin-Ho Chung, a professor in the College of Pharmacy at Seoul National University. "We considered that lead-associated nephrotoxicity must be interpreted in the context of systems biology, rather than as sole and isolated damage to the kidney," Chung says.
Chung and his colleagues conducted a series of in vitro experiments with HK-2 cells 5 and erythrocytes derived from volunteers' blood samples. They showed that, in the absence of erythrocytes, the viability of lead-exposed HK-2 cells was not significantly different from the viability of unexposed HK-2 cells. A separate experiment demonstrated increased PS externalization in lead-exposed erythrocytes. And when lead-exposed erythrocytes were co-cultured with unexposed HK-2 cells, the HK-2 cells not only phagocytized the erythrocytes, but also showed increased production of reactive oxygen species, diminished viability, and greater expression of genes associated with kidney damage.
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Next, the in vitro findings were tested in rats. Samples of blood, spleen, and kidney tissue were collected from rats exposed to 0 or 1,000 ppm lead in drinking water for 12 weeks, then used for biochemical and histological analyses. These analyses revealed statistically significant changes consistent with kidney damage. A second 12-week experiment included tissue samples from rats that received 0, 250, or 1,000 ppm of lead acetate in drinking water; these results also supported the in vitro findings. The in vivo results also ref lected two types of nephrotoxicity seen in epidemiological studies: proximal tubular nephropathy and interstitial fibrosis.
William McClellan, a professor of medicine at Emory University in Atlanta who was not involved in the study, cautions against immediately extrapolating the findings to human health. He also notes that the findings will need replication. McClellan says, "I have a feeling that if they come up with comparable findings [for confirmation], there will be some strong interest in doing some human studies." Julia R. Barrett, MS, ELS, a Madison, WI-based science writer and editor, has written for EHP since 1996. She is a member of the National Association of Science Writers and the Board of Editors in the Life Sciences.
